z-logo
open-access-imgOpen Access
Thrombocytopenia Associated with Linezolid Therapy
Author(s) -
K. Attassi,
Ellie Hershberger,
Rizwan Alam,
Marcus Zervos
Publication year - 2002
Publication title -
clinical infectious diseases
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/338403
Subject(s) - linezolid , medicine , incidence (geometry) , platelet , gastroenterology , surgery , staphylococcus aureus , vancomycin , physics , biology , bacteria , optics , genetics
We evaluated the incidence and clinical characteristics of linezolid-induced thrombocytopenia in 19 patients who were treated with linezolid. Overall, thrombocytopenia (platelet count, <100,000 platelets/mm(3)) was observed in 32% of patients who received linezolid for >10 days; gastrointestinal bleeding was observed in 1 patient and 4 patients required platelet transfusions. These data suggest that even patients who are not considered to be at risk for development of thrombocytopenia should be monitored closely if linezolid therapy is continued for >10 days.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom